<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35429339</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>19</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>19</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1440-0960</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>63</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
            </PubDate>
          </JournalIssue>
          <Title>The Australasian journal of dermatology</Title>
          <ISOAbbreviation>Australas J Dermatol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Scrutinising the role of simvastatin in a patient of Pachyonychia Congenita with KRT6A gene mutation.</ArticleTitle>
        <Pagination>
          <StartPage>e145</StartPage>
          <EndPage>e149</EndPage>
          <MedlinePgn>e145-e149</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/ajd.13835</ELocationID>
        <Abstract>
          <AbstractText>A 25-year-old male patient presented with palmoplantar keratoderma, dystrophic nails, severe plantar pain and oral leukokeratosis since birth. On genetic analysis, a heterozygous KRT6A gene missense mutation (c.1381G &gt; A, p.Glu461Lys in exon 7) was identified by next-generation sequencing technology, consistent with pachyonychia congenita 6a. Oral simvastatin 40 mg was started once daily, and after 16 weeks of therapy, excellent improvement was noted in palmoplantar keratoderma and plantar pain. The maximum thickness of his foot callosity reduced by 4 mm on ultrasonography, and the Dermatology Life Quality Index score dropped significantly by eight points. These benefits may be attributed to inhibition of KRT6A gene expression, modulation of autophagy and mitophagy and Keap1-Nrf2 signalling activation; the latter two mechanisms of statins previously undiscussed in the context of pachyonychia congenita. Simvastatin and other statins are pathogenesis-targeted, disease-modifying therapy in pachyonychia congenita, therefore qualifying as a promising treatment avenue and warranting further clinical trials.</AbstractText>
          <CopyrightInformation>© 2022 Australasian College of Dermatologists.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Sharma</LastName>
            <ForeName>Shruti</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0001-7369-0776</Identifier>
            <AffiliationInfo>
              <Affiliation>Pt BD Sharma Postgraduate Institute of Medical Sciences, Rohtak, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dayal</LastName>
            <ForeName>Surabhi</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Pt BD Sharma Postgraduate Institute of Medical Sciences, Rohtak, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Aggarwal</LastName>
            <ForeName>Kamal</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Pt BD Sharma Postgraduate Institute of Medical Sciences, Rohtak, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gowda V M</LastName>
            <ForeName>Varsha</ForeName>
            <Initials>V</Initials>
            <AffiliationInfo>
              <Affiliation>Pt BD Sharma Postgraduate Institute of Medical Sciences, Rohtak, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kaur</LastName>
            <ForeName>Rupinder</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Pt BD Sharma Postgraduate Institute of Medical Sciences, Rohtak, India.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>16</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Australia</Country>
        <MedlineTA>Australas J Dermatol</MedlineTA>
        <NlmUniqueID>0135232</NlmUniqueID>
        <ISSNLinking>0004-8380</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D019161">Hydroxymethylglutaryl-CoA Reductase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C507569">KRT6A protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000072019">Kelch-Like ECH-Associated Protein 1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D053553">Keratin-6</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051267">NF-E2-Related Factor 2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>AGG2FN16EV</RegistryNumber>
          <NameOfSubstance UI="D019821">Simvastatin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019161" MajorTopicYN="Y">Hydroxymethylglutaryl-CoA Reductase Inhibitors</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000072019" MajorTopicYN="N">Kelch-Like ECH-Associated Protein 1</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053553" MajorTopicYN="N">Keratin-6</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007645" MajorTopicYN="Y">Keratoderma, Palmoplantar</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051267" MajorTopicYN="N">NF-E2-Related Factor 2</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053549" MajorTopicYN="Y">Pachyonychia Congenita</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010146" MajorTopicYN="N">Pain</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019821" MajorTopicYN="N">Simvastatin</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">KRT6A</Keyword>
        <Keyword MajorTopicYN="N">pachyonychia congenita</Keyword>
        <Keyword MajorTopicYN="N">simvastatin</Keyword>
        <Keyword MajorTopicYN="N">statins</Keyword>
        <Keyword MajorTopicYN="N">treatment</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>16</Day>
          <Hour>12</Hour>
          <Minute>3</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35429339</ArticleId>
        <ArticleId IdType="doi">10.1111/ajd.13835</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>REFERENCES</Title>
        <Reference>
          <Citation>Samuelov L, Smith FJD, Hansen CD et al. Revisiting pachyonychia congenita: a case-cohort study of 815 patients. Br. J. Dermatol. 2020; 182: 738-46.</Citation>
        </Reference>
        <Reference>
          <Citation>Goldberg I, Fruchter D, Meilick A et al. Best treatment practices for pachyonychia congenita. J. Eur. Acad. Dermatol. Venereol. 2014; 28: 27985.</Citation>
        </Reference>
        <Reference>
          <Citation>Zieman AG, Coulombe PA. Pathophysiology of pachyonychia congenita-associated palmoplantar keratoderma: new insights into skin epithelial homeostasis and avenues for treatment. Br. J. Dermatol. 2020; 182: 564-73.</Citation>
        </Reference>
        <Reference>
          <Citation>Teng JMC, Bartholomew FB, Patel V et al. Novel treatment of painful plantar keratoderma in pachyonychia congenita using topical sirolimus. Clin. Exp. Dermatol. 2018; 43: 968-71.</Citation>
        </Reference>
        <Reference>
          <Citation>Leachman SA, Hickerson RP, Schwartz ME et al. First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder. Mol. Ther. 2010; 18: 442-6.</Citation>
        </Reference>
        <Reference>
          <Citation>Zhao Y, Gartner U, Smith FJ et al. Statins downregulate K6a promoter activity: a possible therapeutic avenue for pachyonychia congenita. J. Invest. Dermatol. 2011; 131: 1045-52.</Citation>
        </Reference>
        <Reference>
          <Citation>Abdollahimajd F, Rajabi F, Shahidi-Dadras M et al. Pachyonychia congenita: a case report of a successful treatment with rosuvastatin in a patient with a KRT6A mutation. Br. J. Dermatol. 2019; 181: 584-6.</Citation>
        </Reference>
        <Reference>
          <Citation>Theocharopoulos I, O'Toole EA. Stopping pachyonychia congenita plantar pain with a statin? Br. J. Dermatol. 2019; 181: 446-7.</Citation>
        </Reference>
        <Reference>
          <Citation>Lehmann SM, Leube RE, Schwarz N. Keratin 6a mutations lead to impaired mitochondrial quality control. Br. J. Dermatol. 2020; 182: 636-47.</Citation>
        </Reference>
        <Reference>
          <Citation>Ashrafizadeh M, Ahmadi Z, Farkhondeh T et al. Modulatory effects of statins on the autophagy: A therapeutic perspective. J. Cell. Physiol. 2020; 235:3157-68.</Citation>
        </Reference>
        <Reference>
          <Citation>Zanfardino M, Spampanato C, Cicco RD et al. Simvastatin reduces melanoma progression in a murine model. Int. J. Oncol. 2013; 43: 1763-70.</Citation>
        </Reference>
        <Reference>
          <Citation>Andres AM, Hernandez G, Lee P et al. Mitophagy is required for acute cardioprotection by simvastatin. Antioxid. Redox Signal. 2014; 21: 1960-73.</Citation>
        </Reference>
        <Reference>
          <Citation>Weinberg RL, Coulombe PA, Polydefkis M et al. Pain mechanisms in hereditary palmoplantar keratodermas. Br. J. Dermatol. 2019; 182: 543-51.</Citation>
        </Reference>
        <Reference>
          <Citation>Habeos IG, Ziros PG, Chartoumpekis D et al. Simvastatin activates Keap1/Nrf2 signaling in rat liver. J. Mol. Med. 2008; 86: 1279-85.</Citation>
        </Reference>
        <Reference>
          <Citation>Cuadrado A, Manda G, Hassan A et al. Transcription factor NRF2 as a therapeutic target for chronic diseases: a systems medicine approach. Pharmacol. Rev. 2018; 70: 348-83.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
